Recently, the Catogory 1 innovative drug Entinostat Tablets (Chinese trade name: 景助达) of Taizhou EOC Pharma was approved for marketing by China NMPA. It is, in combination with aromatase inhibitors, indicated for the treatment of patients with hormone receptor (HR) positive and human epidermal growth factor receptor-2 (HER-2) negative locally advanced or metastatic breast cancer that is relapsed or progressive after endocrinotherapy.

　　Entinostat Tablets is a histone deacetylase (HDAC) inhibitor, which could selectively inhibit class I and IV HDACs, to suppress cell proliferation, promote terminal differentiation and/or induce apoptosis, so as to exert an anti-tumor effect. The marketing of this drug provides new treatment options for patients with HR+ and HER-2- locally advanced or metastatic breast cancer.